Get the Stockscreener App
0.269
6.37%
-0.0183
VolitionRX Ltd stock is traded at $0.269, with a volume of 1.98M.
It is down -6.37% in the last 24 hours and down -27.43% over the past month.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
See More
Previous Close:
$0.2873
Open:
$0.2875
24h Volume:
1.98M
Relative Volume:
1.49
Market Cap:
$33.03M
Revenue:
$1.29M
Net Income/Loss:
$-29.87M
P/E Ratio:
-0.7472
EPS:
-0.36
Net Cash Flow:
$-14.70M
1W Performance:
-10.24%
1M Performance:
-27.43%
6M Performance:
-54.87%
1Y Performance:
-55.90%
1-Day Range:
$0.266
$0.2995
1-Week Range:
$0.266
$0.31
52-Week Range:
$0.266
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
Name
VolitionRX Ltd
Sector
Industry
Phone
646 650 1351
Address
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.269 | 35.28M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
572.28 | 217.50B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.33 | 164.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
704.20 | 56.49B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
139.68 | 40.44B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.26 | 38.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | H.C. Wainwright | Buy |
| Feb-01-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-17-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-10-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-18 | Initiated | Maxim Group | Buy |
| May-14-18 | Reiterated | The Benchmark Company | Buy |
| Sep-07-16 | Reiterated | Rodman & Renshaw | Buy |
| Feb-01-16 | Initiated | Rodman & Renshaw | Buy |
View All
VolitionRX Ltd Stock (VNRX) Latest News
VolitionRx to eliminate veterinary CEO role as part of cost-realignment - Investing.com Australia
VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment - TipRanks
VolitionRx (VNRX) Unveils Innovative Cancer Detection Method - GuruFocus
Volition (NYSE AMERICAN: VNRX) posts 100% sensitivity in 70-person liquid biopsy study - Stock Titan
VolitionRx’s (VNRX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
VolitionRx downgraded to Hold from Buy at Maxim - MSN
Why VolitionRX Limited stock is a strong buy call2025 Pullback Review & Risk Controlled Daily Plans - Newser
VolitionRx’s Sepsis Biomarker Selected for French National Healthcare Initiative - citybuzz
VolitionRX (VNRX): Analyst Maintains 'Buy' Rating Amidst Stable Price Target | VNRX Stock News - GuruFocus
VolitionRx (NYSE AMERICAN: VNRX) named sole biomarker partner in €6.3M DETECSEPS sepsis detection program - Stock Titan
How VolitionRx Limited stock valuations compare to rivalsGap Up & Fast Entry Momentum Trade Alerts - Newser
VolitionRx (NYSE:VNRX) Lowered to “Hold” Rating by Maxim Group - Defense World
How VolitionRx Limited stock reacts to job market data2025 Market Sentiment & Consistent Growth Equity Picks - Newser
VNRX: Maxim Group Downgrades VolitionRX to Hold | VNRX Stock New - GuruFocus
Healthy Upside Potential: VolitionRX Ltd (VNRX) - Setenews
VolitionRx (VNRX) Insider Trading Activity 2025 - MarketBeat
VolitionRX (VNRX) Analyst Rating Update: Maintain 'Buy' with $5 Target | VNRX Stock News - GuruFocus
VolitionRX Ltd (VNRX) is looking forward to a strong quarter - Setenews
VolitionRx (VNRX) Stock Surges with First Sale of Nu.Q Cancer Assays to European Cancer Center - parameter.io
VolitionRx announces first sale of Nu.Q Cancer assays to French hospital - Investing.com India
VolitionRx announces first sale of Nu.Q Cancer assays to French hospital By Investing.com - Investing.com South Africa
Nu.Q Cancer Assays Sold for Certification at Lyon Center, VolitionRx (NYSE: VNRX) - Stock Titan
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth - Investing.com Australia
Freedom Capital Markets lowers VolitionRX stock price target on delayed revenue growth By Investing.com - Investing.com South Africa
Can VolitionRX Limited stock sustain breakout momentumEarnings Risk Report & Stepwise Trade Execution Plans - newser.com
Will VolitionRX Limited stock beat international competitionQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
What makes VolitionRx Limited stock attractive to growth fundsJuly 2025 Retail & Accurate Trade Setup Notifications - newser.com
Smart tools for monitoring VolitionRx Limited’s price actionWeekly Market Summary & Reliable Breakout Stock Forecasts - newser.com
How strong is VolitionRx Limited stock balance sheet2025 Major Catalysts & Safe Capital Growth Plans - newser.com
How VolitionRX Limited stock trades after rate cutsQuarterly Performance Summary & Expert-Curated Trade Recommendations - newser.com
H.C. Wainwright lowers VolitionRX stock price target on valuation update By Investing.com - Investing.com Nigeria
Are Smart Investors Making the Right Decision? VolitionRX Ltd (VNRX) - Setenews
H.C. Wainwright lowers VolitionRX stock price target on valuation update - Investing.com
VolitionRx price target lowered to $1.50 from $2.50 at H.C. Wainwright - MSN
Reynolds, Volitionrx CEO, buys $7,000 in VNRX stock By Investing.com - Investing.com Nigeria
Reynolds, Volitionrx CEO, buys $7,000 in VNRX stock - Investing.com
CEO Reynolds Buys 20,000 ($7K) Of VolitionRX Ltd [VNRX] - TradingView
[Form 4] VOLITIONRX LTD Insider Trading Activity - Stock Titan
VolitionRX (VNRX) Target Price Lowered by HC Wainwright & Co. | - GuruFocus
VolitionRX (VNRX): Analyst Jason Kolbert Reaffirms Buy Rating wi - GuruFocus
VolitionRx Limited Reports Q3 2025 Financial Growth - MSN
VolitionRx Ltd. Earnings Call Highlights Growth and Partnerships - The Globe and Mail
Using Ichimoku Cloud for VolitionRx Limited technicalsLong Setup & Detailed Earnings Play Alerts - newser.com
Is VolitionRX Limited stock resilient in recession scenariosSell Signal & High Return Trade Opportunity Guides - newser.com
VolitionRx Limited (AMEX:VNRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Volitionrx Ltd earnings missed by $0.01, revenue fell short of estimates - Investing.com Nigeria
Market reaction to VolitionRx Limited’s recent newsTrade Signal Summary & Technical Pattern Based Signals - newser.com
Earnings call transcript: VolitionRx Ltd reports Q3 2025 revenue growth, stock stable - Investing.com Nigeria
VolitionRX Ltd Stock (VNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):